Alpha-Gal E. coli Probiotics for Fish and Poultry Disease Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective solutions for controlling and reducing the severity of myxozoan parasitosis in fish and aspergillosis in poultry, particularly in farmed chicken and turkey, as there are no established treatments or vaccines for these diseases.
Innovation Solution
The use of Escherichia coli strains expressing high levels of α-Gal as probiotics, feed additives, or oral vaccines in non-human animals to modulate α-Gal immunity, specifically targeting pathogens that express α-Gal on their surface, such as Sphaerospora molnari in fish and Aspergillus fumigatus in poultry.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments or vaccines are used for myxozoan parasitosis in fish and aspergillosis in poultry, then disease control is attempted, but no effective solutions exist and mortality rates remain high
Solution Approach 1:
The patent uses E. coli bacteria expressing high levels of α-Gal as an intermediary substance to modulate the immune system. These bacteria serve as a mediator between the host immune system and the pathogens (myxozoan parasites and Aspergillus fungus), inducing protective immune responses without directly attacking the pathogens. The α-Gal expressing E. coli acts as a biological bridge that triggers immune modulation and provides protection against diseases for which no conventional effective treatments exist.
2Reliability
If high levels of anti-α-Gal IgA are present in the system, then immune response is activated, but this can cause severe inflammatory responses and tissue damage
Solution Approach 1:
The patent changes the parameter of immune response intensity by using α-Gal expressing E. coli to modulate anti-α-Gal immunity. Instead of allowing uncontrolled high-level immune activation that causes damage, the bacteria induce a controlled immune response where anti-α-Gal IgA levels are reduced to residual levels, providing protection while avoiding severe inflammatory damage. This parameter modulation transforms the immune response from harmful to protective.
3Object-affected harmful factors
If E. coli strains expressing residual levels of α-Gal are used, then safety is improved, but protective effect against disease is not achieved
Solution Approach 1:
The patent changes the concentration parameter of α-Gal expression in E. coli strains from residual levels to high levels. This parameter change is critical because high-level α-Gal expression by the E. coli bacteria is what induces the protective immune modulation effect. The high-level expressing strains reduce anti-α-Gal IgA to residual levels and provide disease protection, while the bacteria themselves remain safe for use in food-producing animals.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces the severity of infectious diseases by modulating α-Gal immunity, decreasing anti-α-Gal IgA levels in lungs, and promoting protective immune responses in fish and poultry, thereby controlling myxozoan parasitosis and aspergillosis.
Implementation Method 1
the oral administration of Escherichia coli strains expressing high level of α-Gal, modulate the immunity in non-human animals such as fish and poultry infected by pathogen expressing α-Gal on their cell surface
Data Source
AI summary
The present invention concerns an E. coli strains expressing high level of α-Gal, in particular selected in the group consisting of E. coli Nissle 1917 strain, E. coli O111 strain, E. coli O86:B7 strain, and mixture thereof, as a probiotic and/or feed additive and/or oral vaccine in a non-human animal, in particular fish and poultry, to prevent and/or reduce an infectious disease caused by a pathogen expressing α-Gal on its surface.